We may not be ready for patient-reported outcomes (PROs) to be the sole decision-maker yet, but the trend is toward PROs being included more and more in value-based processes, explained Somali Burgess, PhD, senior director, Xcenda.
The United States may not be ready for patient-reported outcomes (PROs) to be the sole decision maker in the contracting process yet, but the trend is toward PROs being included more and more in value-based processes, explained Somali Burgess, PhD, senior director, Xcenda.
Transcript
How has the role of patient-reported outcomes in managed care pharmacy changed over recent years?
I am aware that there’s ongoing discussion around the importance of using patient-reported outcomes, or PROs, or PRO measures, and you’ll see it sometimes referred to as PROMs in value-based payment models as they relate to healthcare delivery, healthcare models, treatment patterns, treatment guidelines. But, I have to say that I haven’t seen as much discussion as it relates to drug pricing and contracting yet. And I think that there are still challenges that payers are facing to get us to that point of recognizing the importance of patient-reported outcomes measures, how they fit into the model, how they fit into the contracting process.
Overall, there’s also a lack, I feel, of consensus among drug manufacturers to realize how to use them but also to determine which validated measures should be used. So, as long as there’s a lack of consensus, it’s difficult to come to that standardized or that decision on which to use and how to use. While you can definitely use PRO measures to demonstrate efficacy, as part of a value-based model or the contracting process, there are challenges around collecting that data because there isn’t agreement on which ones to use. The perspective of the patient and the clinician has to be taken into consideration, and then to have a standardized method of data collection.
So, we may not be ready for patient-reported outcome measures to be sole decision-making points yet, but they are definitely being included, and I feel the trend is towards including PRO measures more and more in that value-based process.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More